Pharma
Navigating payer challenges in rare disease
Clinical and economic evidence generation across rare diseases is challenging due to intrinsic disease characteristics, misalignment on treatment costs, and inadequate traditional evaluation frameworks. Therefore, rare disease products face unique payer challenges, which need to be comp...
Improving adherence in Asthma treatment
Asthma, a common respiratory disorder affects more than 8 million people in the UK alone [1]. Despite the availability of effective treatments, inhaled corticosteroids (ICS) which are the mainstay of asthma treatment, often show limited efficacy because of suboptimal patient adherence. ...
AI at the Frontier: Empowering Early Career Professionals in Drug Discovery
ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Join us for an insightful webinar where industry experts will delve into the transformative role of AI in revolutionising drug discovery and how it will impact your career in drug discove...
ELRIG UK and SRG announce partnership to advance life science professionals in drug discovery
Partnership endorses mission to facilitate career progression and support life science industry growth. ...
Cambridge AI Club - May Theme - "Feature Selection Methods"
The AI Club brings together the Biomedical AI and Machine Learning community in Cambridge to discuss common themes and explore different topics and methodologies. ...
Guardtech land Medilink Midlands Business Awards Innovation nomination with CleanCube
The Group’s unique portable container laboratories will be up for the gong at Medilink’s Athena Leicester showpiece next month ...
Gravity x Milner Therapeutics Institute Biotech Matchmaking Event
Are you interested in working for a biotech company?
SPT Labtech appoints Rob Walton as New Chief Executive Officer
Melbourn, UK, 11 April 2024 —
Understanding and managing Interstitial Lung Disease
Interstitial lung disease (ILD) is an umbrella term used to describe a group of highly variable restrictive lung diseases, which are characterised by inflammation and pulmonary fibrosis (scarring of the lungs). These diseases primarily affect the lung interstitium, the tissue and the sp...
Nxera Pharma joins the World Orphan Drug Alliance
Tokyo, Japan and Cambridge, UK, 8 April 2024 – Nxera Pharma Co. Ltd, formerly known as Sosei Group or Sosei Heptares – announces it has joined the World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare disease...